Other Mutations: HRAS

NCT03155620: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, ATM, ALK, BRAF, EZH2, FGFR, HRAS, MAPK, mTOR, NTRK, PI3K, Rb+, RET, ROS, TSC, DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients over the age of 21
https://ClinicalTrials.gov/show/NCT03155620

Up ↑